1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Inspecs Group Plc

Inspecs Group Plc

LLSE:SPEC
90.00
GBX
0.00
(0.00%)
7.27BMarket Cap
Jun 11Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.21
0.38
0.64
0.5
0.37
1.33
1.98
2
1.9
1.89
- -
Basic EPS, GAAP
0.01
-0.03
0.04
0.05
-0.07
-0.03
-0.06
-0.01
-0.05
-0.09
- -
Free Cash Flow per Basic Share
0.02
0.04
0.04
0.06
-0.03
0.07
- -
0.07
0.04
-0.02
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
Book Value per Share
4.03
29.47
0.25
0.25
0.77
0.78
1.06
1.02
0.92
0.78
0.78
Tangible Book Value per Share
3.57
-20.16
-0.08
0.01
0.09
0.08
0.16
0.18
0.12
0.06
0.06
Basic Weighted Avg Shares
71
71
71
71
69
101
102
102
102
102
102
Sales/Revenue/Turnover
15
27
45
35
25
135
201
203
193
192
- -
Operating Margin (%)
5.06
6.2
16.44
12.97
-6.2
0.63
-0.59
1.42
3.05
2.97
- -
Depreciation Expense
- -
2
2
2
2
8
14
13
12
12
- -
Net Income, GAAP
- -
-2
3
4
-5
-3
-6
-1
-5
-10
- -
Effective Tax Rate (%)
0.65
- -
3.48
12.35
- -
- -
- -
563.72
228.78
- -
- -
Profit Margin (%)
3.21
-6.79
6.11
10.51
-18.8
-2.21
-3.14
-0.49
-2.38
-4.99
- -
Working Capital
1
-12
- -
2
30
26
-1
32
22
26
26
LT Debt
1
1
13
7
38
38
17
48
45
44
44
Total Equity
1
11
18
18
78
79
108
104
93
80
80
Return on Invested Capital (%)
- -
- -
21.15
11.5
- -
- -
- -
-7.59
-4.58
- -
- -
Return on Capital (%)
- -
- -
11.94
12.86
- -
- -
- -
-11.44
-5.85
- -
- -
Return on Common Equity (%)
- -
-30.07
19.28
20.62
-9.94
-3.77
-6.76
-0.94
-4.69
-11.06
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
18
15
15
LT Borrowings
35
- -
36
LT Finance Leases
9
- -
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
102
102
102
Market Capitalization
46
50
73

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
108
100
103
Cash, Cash Equivalents & STI
24
23
16
Accounts Receivable, Net
27
25
27
Inventories
46
41
47
Total Current Liabilities
86
69
77
Payables & Accruals
- -
- -
- -
ST Debt
18
15
15
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.72%
-14.33%
Free Cash Flow
- -
105.23%
-149.78%
Net Income, GAAP
- -
91.99%
107.42%
Sales/Revenue/Turnover
- -
94.85%
-0.85%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
203
2024
- -
- -
193
2025
- -
- -
192

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.05
2025
- -
- -
-0.09

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Richard David Peck
Full Time Employees
1,705
Sector
Health technology
Industry
Medical specialties
Address
7-10 Kelso Place Bath SO United Kingdom BA1 3AU
IPO Date
Feb 27, 2020
Website
inspecs.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
INSPECS Group plc designs, manufactures and distributes eyewear solutions worldwide, including frames, lenses and low vision aids across optical, sunglasses and safety categories; its offerings encompass branded products under licensed fashion, sports and lifestyle labels such as Superdry, Savile Row and Barbour, proprietary designs and unbranded private label eyewear for original equipment manufacturers (OEM). The company operates a vertically integrated model covering design, production and distribution through segments including Frames and Optics for product distribution, Wholesale for OEM and manufacturing and Lenses for lens manufacturing and distribution; it serves global optical and non-optical retailers, distributors and independent opticians via a network spanning over 80 countries and approximately 75,000 points of sale. INSPECS maintains manufacturing facilities in Vietnam, China, the UK and Italy, with offices and subsidiaries in the United Kingdom, Germany, Portugal, Scandinavia, the United States and China including Hong Kong, Macau and Shenzhen. Founded in 1988 and headquartered in Bath, Somerset, United Kingdom, the company has recently received multiple unsolicited non-binding acquisition proposals including from H2 Equity Partners Ltd, a consortium of Risk Capital Partners and Ian Livingstone for its entire share capital, and from Safilo Group S.p.A. for its Eschenbach Group and BoDe businesses; it completed construction of a new Vietnam manufacturing facility on time and budget to boost capacity and efficiencies, expanded distribution partnerships with major US and Canadian retailers from Q4 2024 alongside 45% travel retail revenue growth, and integrated Inspecs USA operations including warehouse consolidation.